menu
    • menu
    [{"orgOrder":0,"company":"Hospital Ruber Internacional","sponsor":"Zogenix","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SPAIN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Fenfluramine","moa":"Serotonin 1d (5-HT1d) receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"Hospital Ruber Internacional","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hospital Ruber Internacional \/ Zogenix","highestDevelopmentStatusID":"11","companyTruncated":"Hospital Ruber Internacional \/ Zogenix"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Fenfluramine","moa":"Serotonin 1d (5-HT1d) receptor","graph1":"Neurology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"University of Oxford","sponsor":"Zogenix | National Institute for Health Research, UK","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Fenfluramine","moa":"Serotonin 1d (5-HT1d) receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"University of Oxford \/ Zogenix | National Institute for Health Research, UK","highestDevelopmentStatusID":"11","companyTruncated":"University of Oxford \/ Zogenix | National Institute for Health Research, UK"},{"orgOrder":0,"company":"University of Colorado, Denver","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Fenfluramine","moa":"Serotonin 1d (5-HT1d) receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"University of Colorado, Denver","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"University of Colorado, Denver \/ UCB Pharma S.A","highestDevelopmentStatusID":"11","companyTruncated":"University of Colorado, Denver \/ UCB Pharma S.A"},{"orgOrder":0,"company":"University Health Network, Toronto","sponsor":"Zogenix","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Fenfluramine","moa":"Serotonin 1d (5-HT1d) receptor","graph1":"Neurology","graph2":"Phase III","graph3":"University Health Network, Toronto","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"University Health Network, Toronto \/ Zogenix","highestDevelopmentStatusID":"10","companyTruncated":"University Health Network, Toronto \/ Zogenix"},{"orgOrder":0,"company":"Zogenix","sponsor":"KU Leuven","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Fenfluramine","moa":"Serotonin 1d (5-HT1d) receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zogenix \/ KU Leuven","highestDevelopmentStatusID":"8","companyTruncated":"Zogenix \/ KU Leuven"}]

    Find Clinical Drug Pipeline Developments & Deals for (+-)-Fenfluramine

    Menu

    (+-)-Fenfluramine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            University of Colorado, Denver

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            University of Colorado, Denver

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fenfluramine

                            Therapeutic Area : Neurology

                            Study Phase : Phase IV

                            Sponsor : UCB Pharma S.A

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Assessment of Safety of the Use of Fenfluramine in Children With Dravet Syndrome Under 24 Months of Age

                            Details : Fenfluramine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Epilepsies, Myoclonic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 19, 2024

                            Lead Product(s) : Fenfluramine

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase IV

                            Sponsor : UCB Pharma S.A

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            UCB Pharma S.A

                            Belgium arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            UCB Pharma S.A

                            Belgium arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fenfluramine

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Ye...

                            Details : Fenfluramine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Epilepsies, Myoclonic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 07, 2023

                            Lead Product(s) : Fenfluramine

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            University Health Network, Toronto

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            University Health Network, Toronto

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fenfluramine

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Zogenix

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Fenfluramine for Adult Dravet Patients

                            Details : Fenfluramine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Epilepsies, Myoclonic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 29, 2022

                            Lead Product(s) : Fenfluramine

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Zogenix

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Hospital Ruber Internacional

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Hospital Ruber Internacional

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fenfluramine

                            Therapeutic Area : Neurology

                            Study Phase : Phase IV

                            Sponsor : Zogenix

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Fenfluramine for the Treatment of Different Types of Developmental and Epileptic Encephalopathies: a Pilot Tri...

                            Details : Fenfluramine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Drug Resistant Epilepsy.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 10, 2022

                            Lead Product(s) : Fenfluramine

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase IV

                            Sponsor : Zogenix

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            University of Oxford

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            University of Oxford

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fenfluramine

                            Therapeutic Area : Neurology

                            Study Phase : Phase IV

                            Sponsor : Zogenix | National Institute for Health Research, UK

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Fenfluramine and Cognition

                            Details : Fenfluramine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Cognition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 30, 2021

                            Lead Product(s) : Fenfluramine

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase IV

                            Sponsor : Zogenix | National Institute for Health Research, UK

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Zogenix

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Zogenix

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fenfluramine

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : KU Leuven

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Add-on Therapy With Low Dose Fenfluramine in Lennox Gastaut Epilepsy

                            Details : Fenfluramine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Epilepsy.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 13, 2016

                            Lead Product(s) : Fenfluramine

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : KU Leuven

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth